Is Kailera Therapeutics, Inc. (KLRA) a Buy, Sell, or Hold?
NASDAQ : KLRA
Kailera Therapeutics, Inc.
$18.55 USD
$0.23 (1.26%)
- Volume
- 342.89K
- Average Volume
- 796.3K
- Market Capitalization
- $2.4B
- P/E Ratio
- -14.72
- Dividend Yield
- 0.00%
- Price Target
- $42.00
- Year High
- $28.23
- Year Low
- $17.61
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.01
Insider Activity Summary (Last 12 Months)
Insiders Buying
29
Insiders Selling
11
Amount of Insider Selling
$93.75M
KLRA Insider Buying/Selling by Quarter
KLRA Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Tregoning Kathleen | officer: See Remarks | 2026-07-06 | A-Award | 23.3 | 2026-07-08 |
| Tregoning Kathleen | 2026-06-29 | 0 | 2026-07-08 | ||
| Renaud Ronald C JR | director, officer: CEO & President | 2026-06-09 | M-Exempt | 5.25 | 2026-06-11 |
| Renaud Ronald C JR | director, officer: CEO & President | 2026-06-09 | M-Exempt | 5.25 | 2026-06-11 |
| RTW INVESTMENTS, LP | 10 percent owner | 2026-04-20 | P-Purchase | 16 | 2026-04-22 |
| RTW INVESTMENTS, LP | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-22 |
| RTW INVESTMENTS, LP | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-22 |
| RTW INVESTMENTS, LP | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-22 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-22 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-22 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-22 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-22 |
| BAIN CAPITAL INVESTORS LLC | 10 percent owner | 2026-04-20 | P-Purchase | 16 | 2026-04-20 |
| BAIN CAPITAL INVESTORS LLC | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| BAIN CAPITAL INVESTORS LLC | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Koppel Adam | director, 10 percent owner: | 2026-04-20 | P-Purchase | 16 | 2026-04-20 |
| Koppel Adam | director, 10 percent owner: | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Koppel Adam | director, 10 percent owner: | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Koppel Adam | director, 10 percent owner: | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Koppel Adam | director, 10 percent owner: | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Koppel Adam | director, 10 percent owner: | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2026-04-20 | P-Purchase | 16 | 2026-04-20 |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Kaplan Andrew T. | director, 10 percent owner: | 2026-04-20 | P-Purchase | 16 | 2026-04-20 |
| Kaplan Andrew T. | director, 10 percent owner: | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Kaplan Andrew T. | director, 10 percent owner: | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Kaplan Andrew T. | director, 10 percent owner: | 2026-04-20 | C-Conversion | 0 | 2026-04-20 |
| Cloghessy Paula | officer: Chief People Officer | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Akamine Scott | officer: Chief Legal Officer | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Renaud Ronald C JR | director, officer: CEO & President | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Burgess Paul D. | officer: See Remarks | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| MILLIGAN JOHN F | director | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Coleman Jamie Beth | officer: Chief Commercial Officer | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| MACKAY MARTIN | director | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Wasserman Scott M. | officer: Chief Medical Officer | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Hite Christopher | director | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Clyburn Frank | director | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Pagan Douglas W. | officer: Chief Financial Officer | 2026-04-16 | A-Award | 16 | 2026-04-20 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | 2026-04-16 | 0 | 2026-04-16 | |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | 2026-04-16 | 0 | 2026-04-16 | |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | 2026-04-16 | 0 | 2026-04-16 | |
| Koppel Adam | director, 10 percent owner: | 2026-04-16 | 0 | 2026-04-16 | |
| Koppel Adam | director, 10 percent owner: | 2026-04-16 | 0 | 2026-04-16 | |
| BAIN CAPITAL INVESTORS LLC | 10 percent owner | 2026-04-16 | 0 | 2026-04-16 | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2026-04-16 | 0 | 2026-04-16 | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2026-04-16 | 0 | 2026-04-16 | |
| Kaplan Andrew T. | director, 10 percent owner: | 2026-04-16 | 0 | 2026-04-16 | |
| Burgess Paul D. | officer: See Remarks | 2026-04-16 | 5.25 | 2026-04-16 | |
| Burgess Paul D. | officer: See Remarks | 2026-04-16 | 7.24 | 2026-04-16 | |
| Wasserman Scott M. | officer: Chief Medical Officer | 2026-04-16 | 5.25 | 2026-04-16 | |
| Wasserman Scott M. | officer: Chief Medical Officer | 2026-04-16 | 7.24 | 2026-04-16 | |
| Pagan Douglas W. | officer: Chief Financial Officer | 2026-04-16 | 10.09 | 2026-04-16 | |
| Coleman Jamie Beth | officer: Chief Commercial Officer | 2026-04-16 | 5.4 | 2026-04-16 | |
| Coleman Jamie Beth | officer: Chief Commercial Officer | 2026-04-16 | 7.24 | 2026-04-16 | |
| RTW INVESTMENTS, LP | 10 percent owner | 2026-04-16 | 0 | 2026-04-16 | |
| RTW INVESTMENTS, LP | 10 percent owner | 2026-04-16 | 0 | 2026-04-16 | |
| MACKAY MARTIN | director | 2026-04-16 | 11.56 | 2026-04-16 | |
| Liu Yuting | 2026-04-16 | 0 | 2026-04-16 | ||
| Hite Christopher | director | 2026-04-16 | 5.4 | 2026-04-16 | |
| Hite Christopher | director | 2026-04-16 | 7.24 | 2026-04-16 | |
| Cloghessy Paula | officer: Chief People Officer | 2026-04-16 | 5.25 | 2026-04-16 | |
| Cloghessy Paula | officer: Chief People Officer | 2026-04-16 | 5.4 | 2026-04-16 | |
| Cloghessy Paula | officer: Chief People Officer | 2026-04-16 | 7.24 | 2026-04-16 | |
| Renaud Ronald C JR | director, officer: CEO & President | 2026-04-16 | 5.25 | 2026-04-16 | |
| Renaud Ronald C JR | director, officer: CEO & President | 2026-04-16 | 7.24 | 2026-04-16 | |
| Clyburn Frank | director | 2026-04-16 | 7.24 | 2026-04-16 | |
| Akamine Scott | officer: Chief Legal Officer | 2026-04-16 | 5.25 | 2026-04-16 | |
| Akamine Scott | officer: Chief Legal Officer | 2026-04-16 | 7.24 | 2026-04-16 | |
| MILLIGAN JOHN F | director | 2026-04-16 | 5.25 | 2026-04-16 | |
| MILLIGAN JOHN F | director | 2026-04-16 | 7.24 | 2026-04-16 | |
| CANADA PENSION PLAN INVESTMENT BOARD | 10 percent owner | 2026-04-16 | 0 | 2026-04-16 | |
| Stuart Partners, LLC | 10 percent owner | 2026-04-16 | 0 | 2026-04-16 |